CMXC Announces Results of Preliminary Analysis of Metabolomic Assays
News Feb 27, 2015
Cell MedX Corp. has announced that it has received the first results of the analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.
The pilot clinical discovery phase trial in two diabetic subjects was performed in January 2015. Its main objective was to examine the short term metabolic impact of a single treatment with e-balance technology. Additional assays are pending.
Analysis of this early data set indicates substantial changes in at least two key pathways that would correlate with improvements in glucose and lipid metabolism. These findings will inform further experimentation, including the Phase 1B clinical trial, which begins recruiting in March 2015.
The analysis of the samples was conducted by The Metabolomics Innovation Centre at the University of Alberta (“TMIC”), whose analytic and informatics toolsets and translational “omics” expertise allows for cost-effective and more accurate results of assays.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Researchers Find a Way to Separate Side Effects of Opioid Drugs Reducing RiskNews
Scientists have discovered a way to separate these two effects -- pain relief and breathing, opening a window of opportunity to make effective pain medications without the risk of respiratory failure.READ MORE